1-8 of 8
Peter E. Schwartz
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)

Sangini S. Sheth, Ji Eun Oh, Stefania Bellone, Eric R. Siegel, Michelle Greenman, Levent Mutlu, Blair McNamara, Shefali Pathy, Mitchell Clark, Masoud Azodi, Gary Altwerger, Vaagn Andikyan, Gloria Huang, Elena Ratner, Daniel J. Kim, Akiko Iwasaki, Angelique W. Levi, Natalia Buza, Pei Hui, Sean Flaherty, Peter E. Schwartz, Alessandro D. Santin
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (9): 1768–1777.
https://doi.org/10.1158/1078-0432.CCR-23-3639
Published: 01 May 2024
View articletitled, Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)
Open the PDF for Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147) in another window
Includes: Supplementary data
Journal Articles

Randomized Phase II Trial of Carboplatin–Paclitaxel Compared with Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis

Amanda N. Fader, Dana M. Roque, Eric Siegel, Natalia Buza, Pei Hui, Osama Abdelghany, Setsuko Chambers, Angeles Alvarez Secord, Laura Havrilesky, David M. O'Malley, Floor J. Backes, Nicole Nevadunsky, Babak Edraki, Dirk Pikaart, William Lowery, Karim ElSahwi, Paul Celano, Stefania Bellone, Masoud Azodi, Babak Litkouhi, Elena Ratner, Dan-Arin Silasi, Peter E. Schwartz, Alessandro D. Santin
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (15): 3928–3935.
https://doi.org/10.1158/1078-0432.CCR-20-0953
Published: 03 August 2020
View articletitled, Randomized Phase II Trial of Carboplatin–Paclitaxel Compared with Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis
Open the PDF for Randomized Phase II Trial of Carboplatin–Paclitaxel Compared with Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis in another window
Includes: Supplementary data
Journal Articles

Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer

Elena Bonazzoli, Federica Predolini, Emiliano Cocco, Stefania Bellone, Gary Altwerger, Gulden Menderes, Luca Zammataro, Anna Bianchi, Francesca Pettinella, Francesco Riccio, Chanhee Han, Ghanshyam Yadav, Salvatore Lopez, Aranzazu Manzano, Paola Manara, Natalia Buza, Pei Hui, Serena Wong, Babak Litkouhi, Elena Ratner, Dan-Arin Silasi, Gloria S. Huang, Masoud Azodi, Peter E. Schwartz, Joseph Schlessinger, Alessandro D. Santin
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (19): 4845–4853.
https://doi.org/10.1158/1078-0432.CCR-18-0864
Published: 01 October 2018
View articletitled, Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer
Open the PDF for Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer in another window
Includes: Supplementary data
Journal Articles

Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement

Stefania Bellone, Natalia Buza, Jungmin Choi, Luca Zammataro, Laurie Gay, Julia Elvin, David L. Rimm, Yuting Liu, Elena S. Ratner, Peter E. Schwartz, Alessandro D. Santin
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (14): 3282–3291.
https://doi.org/10.1158/1078-0432.CCR-17-1805
Published: 15 July 2018
View articletitled, Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement
Open the PDF for Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement in another window
Includes: Supplementary data
Journal Articles

SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression

Gulden Menderes, Elena Bonazzoli, Stefania Bellone, Jonathan Black, Federica Predolini, Francesca Pettinella, Alice Masserdotti, Luca Zammataro, Gary Altwerger, Natalia Buza, Pei Hui, Serena Wong, Babak Litkouhi, Elena Ratner, Dan-Arin Silasi, Masoud Azodi, Peter E. Schwartz, Alessandro D. Santin
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (19): 5836–5845.
https://doi.org/10.1158/1078-0432.CCR-16-2862
Published: 01 October 2017
View articletitled, SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression
Open the PDF for SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression in another window
Journal Articles

Regression of Chemotherapy-Resistant Polymerase ϵ (POLE) Ultra-Mutated and MSH6 Hyper-Mutated Endometrial Tumors with Nivolumab

Alessandro D. Santin, Stefania Bellone, Natalia Buza, Jungmin Choi, Peter E. Schwartz, Joseph Schlessinger, Richard P. Lifton
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (23): 5682–5687.
https://doi.org/10.1158/1078-0432.CCR-16-1031
Published: 30 November 2016
View articletitled, Regression of Chemotherapy-Resistant Polymerase ϵ (POLE) Ultra-Mutated and MSH6 Hyper-Mutated Endometrial Tumors with Nivolumab
Open the PDF for Regression of Chemotherapy-Resistant Polymerase ϵ (POLE) Ultra-Mutated and MSH6 Hyper-Mutated Endometrial Tumors with Nivolumab in another window
Journal Articles

Reply to the Letters to the Editor from Greene et al.

Gil Mor, Peter E. Schwartz, Herbert Yu
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (22): 7577–7579.
https://doi.org/10.1158/1078-0432.CCR-08-2621
Published: 14 November 2008
View articletitled, Reply to the Letters to the Editor from Greene et al.
Open the PDF for Reply to the Letters to the Editor from Greene et al. in another window
Journal Articles

Diagnostic Markers for Early Detection of Ovarian Cancer

Irene Visintin, Ziding Feng, Gary Longton, David C. Ward, Ayesha B. Alvero, Yinglei Lai, Jeannette Tenthorey, Aliza Leiser, Ruben Flores-Saaib, Herbert Yu, Masoud Azori, Thomas Rutherford, Peter E. Schwartz, Gil Mor
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (4): 1065–1072.
https://doi.org/10.1158/1078-0432.CCR-07-1569
Published: 15 February 2008
View articletitled, Diagnostic Markers for Early Detection of Ovarian Cancer
Open the PDF for Diagnostic Markers for Early Detection of Ovarian Cancer in another window
Includes: Supplementary data